The Federal Trade Commission can go after six years of Cephalon’s profits in a reverse-payment case against the pharmaceutical company, a federal judge has ruled.
Reverse-payment settlements are the deals made by major pharmaceutical companies with generic drugmakers in order to keep the cheaper drugs off the market and, in this case, Cephalon had made deals with four generic drugmakers ranging from $25 million to $164 million to protect its name-brand wakefulness drug called Provigil.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
